Results 1 to 10 of about 15,087 (174)

Recurrence of vulvar carcinoma: A multidisciplinary approach. [PDF]

Gynecol Oncol Rep, 2019
Although oncogynaecological management of bulky vulvar tumors tends to minimally-invasive approaches preceded by neoadjuvant therapies, ultra-radical surgery with curative intent may still have an important role. These procedures remain associated with significant short and long-term complications, imposing the need for novel reconstructive techniques [
Rei M, Mota R, Paiva V, Duarte A, Costa J, Costa A.   +5 more
europepmc   +6 more sources

Vulvar carcinoma: dilemma, debates, and decisions. [PDF]

Cancer Manag Res, 2018
Vulvar carcinoma is a rare and aggressive gynecological malignancy. It affects elderly females, with the mean age at diagnosis being 55-60 years. Regional metastasis to inguinal lymph nodes is common. There is a high incidence of pelvic node involvement, especially in those with pathologically positive inguinal nodes.
Mitra S, Sharma MK, Kaur I, Khurana R, Modi KB, Narang R, Mandal A, Dutta S.   +7 more
europepmc   +7 more sources

Mohs Micrographic Surgery Versus Wide Local Excision in the Treatment of Anogenital Squamous Cell Carcinoma: A Systematic Review. [PDF]

Int J Dermatol
ABSTRACT Primary anogenital squamous cell carcinoma (SCC) is a locally aggressive malignancy that requires careful consideration of surgical margins. Anogenital SCC impacts the quality of life due to tissue removal, scarring, and sexual dysfunction. Mohs micrographic surgery (MMS) offers a compelling alternative to wide local excision (WLE) due to its ...
Yadlapati S, Rosa-Nieves PM, Lauck KC, Tolkachjov SN.   +3 more
europepmc   +2 more sources

Therapy for Primary Vulvar Carcinoma [PDF]

Geburtshilfe und Frauenheilkunde, 2014
The rather rare vulvar cancer is almost always a squamous cell carcinoma that mostly develops from an underlying VIN or HPV infection. In addition, lichen sclerosus et atrophicans, immune deficiency, nicotine abuse or anogenital intraepithelial neoplasias may play a role in the pathogenesis.
EF Solomayer, I. Juhasz-Boess, D. Herr
openaire   +3 more sources

Vulvar basal cell carcinoma

Indian Journal of Pathology and Microbiology, 2012
Although the basal cell carcinoma (BCC) is the most common malignancy of skin, it is rarely seen in vulva and constitutes 2% to 4% of all vulvar cancers. The cause is unknown but, chronic vulvar irritation is the most important underlying factor. The patients over 60 years are affected more frequently than younger ones.
Erdogan Nilsen Yildirim, Mustafa Kara, E Colgecen   +2 more
openaire   +3 more sources

Vulvar carcinoma [PDF]

Cancer, 2002
AbstractBACKGROUNDThe objective of this study was to determine whether modifications in the treatment of patients with vulvar carcinoma influence the rates of recurrence and survival.METHODSBetween 1982 and 1997, 253 patients with T1 and T2 invasive squamous cell carcinoma of the vulva were treated by essentially the same team of gynecologic ...
Hullu, J.A. de, Hollema, H., Lolkema, S., Boezen, M., Boonstra, H., Burger, M.P.M., Aalders, J.G., Mourits, M.J.E., Zee, A. van der   +8 more
openaire   +4 more sources

Vulvar Sweat Gland Carcinomas

Journal of Urology, 1985
Sweat gland carcinomas constitute less than 10% of all malignant tumors of the vulva, including those associated with extramammary Paget's disease (EPD). The histopathologic diagnosis of vulvar sweat gland carcinomas is difficult because of their rarity; their resemblance to metastatic carcinomas of the internal female genitalia, kidneys, and other ...
John R. Goellner, W.P.D. Su, M.R. Wick, James T. Wolfe   +3 more
openaire   +3 more sources

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

International Journal of Cancer, EarlyView.
What's New? Currently, no published data on homologous recombination deficiency (HRD) testing in the setting of molecular tumor boards exist. This study in a cohort of 237 patients encompassing 24 different tumor entities assessed by a molecular tumor board shows that inactivating alterations of BRCA1/2 are not always associated with an elevated ...
Christoph Schubart, Lars Tögel, Maria Giulia Carta, Philip Hetzner, Lina Helbig, Charlotte Zaglas, Maria Ziegler, Robert Stöhr, Annett Hölsken, Juliane Hoyer, Fulvia Ferrazzi, Clemens Neufert, Sebastian Lettmaier, Marianne Pavel, Henriette Golcher, Sarina K. Mueller, Florian Fuchs, Carla E. Schulmeyer, Matthias W. Beckmann, Bernd Wullich, Abbas Agaimy, Andre Reis, Arndt Hartmann, Norbert Meidenbauer, Silvia Spoerl, Florian Haller, Evgeny A. Moskalev   +26 more
wiley   +1 more source

Association between body mass index, obesity, and vulvar cancer recurrence

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective The objective of this paper is to study the association between obesity and tumor recurrence in patients with vulvar cancer. Methods This is a retrospective study including vulvar cancer patients from 2003 to 2022. Our primary outcome was progression‐free survival (PFS) stratified by status of obesity, defined as body mass index (BMI)
Yossi Tzur, Angela Magri, Raanan Meyer, Melica Nourmoussavi Brodeur, Shannon Salvador, Susie Lau, Walter Gotlieb, Gabriel Levin   +7 more
wiley   +1 more source

CO2 laser therapy versus topical imiquimod for the treatment of vulvar high‐grade intraepithelial lesions: A retrospective cohort study

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objectives To compare topical imiquimod with CO2 laser therapy for the treatment of a first episode of vulvar high‐grade squamous intraepithelial lesions (vHSIL), to identify serious adverse effects of both treatment modalities, and to examine risk factors for treatment failure.
Elizabeth Svoboda, Mélanie Benoit, Chelsea Almadin, Valérie Archer‐Déjoie, Coralie Michaud, Julie Lacaille, Laurence Simard‐Émond, Annick Pina, François Gougeon, Marie‐Hélène Mayrand   +9 more
wiley   +1 more source